KNIGHT THERAPEUTICS


Associated tags: TSX, Therapy, GUD, Knight, Patient, Pharmaceutical industry

Locations: LATIN AMERICA, CANADA, PARAGUAY, URUGUAY, BRAZIL, IRELAND, SWITZERLAND, CHINA, ARGENTINA, COLOMBIA, ARDS, UNITED STATES, EUROPE, MEXICO, PERU, ECUADOR, CHILE, GILEAD, BOLIVIA, MONTREAL, QC, CA, NEW YORK CITY, QUEBEC

Knight Therapeutics Announces Launch of Minjuvi® in Brazil

Retrieved on: 
Thursday, February 29, 2024

MONTREAL, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today the launch of Minjuvi® (tafasitamab) by its Brazilian affiliate, United Medical Ltda.

Key Points: 
  • MONTREAL, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today the launch of Minjuvi® (tafasitamab) by its Brazilian affiliate, United Medical Ltda.
  • Additionally, in October 2023, Knight received pricing approval for Minjuvi® from the Drugs Market Regulation Chamber (“CMED”).
  • “In line with Knight’s commitment to advancing healthcare in Latin America, we are excited to launch Minjuvi in Brazil, an innovative treatment option for addressing a current unmet medical need,” said Samira Sakhia, Knight Therapeutics President and CEO.
  • “Knight’s team in Brazil is thrilled to make Minjuvi® available to health care professionals and centers, improving DLBCL patient care in the country,” said Cristiane Coelho, Knight Therapeutics Brazil General Manager.

Knight Therapeutics Inc. Celebrates its First Decade of Success

Retrieved on: 
Wednesday, February 28, 2024

MONTREAL, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today that it is marking its 10-year anniversary, and celebrating a decade of expansion and growth.

Key Points: 
  • MONTREAL, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today that it is marking its 10-year anniversary, and celebrating a decade of expansion and growth.
  • Knight has invested over $925 million to build its unique pan-American (ex US) platform of innovative and branded generic pharmaceuticals.
  • Today, Knight has over 700 talented employees operating in Canada and 10 Latin American markets.
  • Since the completion of the acquisition of Biotoscana, Knight has entered into 11 new partnerships for 13 innovative and branded generic products.

Knight Therapeutics Announces Regulatory Submission of Fostamatinib in Brazil

Retrieved on: 
Wednesday, February 21, 2024

MONTREAL, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Brazilian affiliate, United Medical Ltda., has submitted a marketing authorization application to ANVISA, the Brazilian health regulatory agency, for fostamatinib for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.

Key Points: 
  • MONTREAL, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Brazilian affiliate, United Medical Ltda., has submitted a marketing authorization application to ANVISA, the Brazilian health regulatory agency, for fostamatinib for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.
  • Knight has previously submitted marketing authorization applications for fostamatinib in Colombia and Mexico.
  • “This submission of fostamatinib demonstrates Knight’s continued execution of our strategy of leveraging our solid platform and expertise to bring innovative therapies for important unmet healthcare needs in Latin America,” said Samira Sakhia, President and Chief Executive Officer of Knight Therapeutics Inc.
    On May 24, 2022, Knight announced that it entered into an agreement with Rigel Pharmaceuticals, Inc. for the exclusive rights to commercialize fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor, in Latin America.
  • Fostamatinib is commercially available in the United States under the brand name TAVALISSE® and in Europe under the brand name TAVLESSE® for the treatment of adult chronic ITP.

Knight Therapeutics Announces Launch of Bijuva® in Canada

Retrieved on: 
Tuesday, February 6, 2024

MONTREAL, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight"), a Pan-American (ex-USA) specialty pharmaceutical company, announced today the launch of BIJUVA® (estradiol and progesterone) capsules in Canada.

Key Points: 
  • MONTREAL, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight"), a Pan-American (ex-USA) specialty pharmaceutical company, announced today the launch of BIJUVA® (estradiol and progesterone) capsules in Canada.
  • VMS affects 60% to 80% of women entering menopause1 and are commonly known as hot flashes or flushes and night sweats.
  • Knight and TherapeuticsMD signed a license agreement in July 2018 pursuant to which TherapeuticsMD granted Knight the exclusive Canadian commercialization rights to BIJUVA®.
  • Under the terms of the license agreement related BIJUVA® in Canada, Knight will pay TherapeuticsMD sales milestone fees and royalties based upon certain aggregate annual sales of BIJUVA® in Canada.

Knight Therapeutics Enters into Exclusive License Agreement with Amneal Pharmaceuticals for IPX203

Retrieved on: 
Thursday, January 25, 2024

MONTREAL, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today that it has entered into an exclusive license agreement with Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) ("Amneal"), granting Knight the exclusive rights to seek regulatory approval and commercialize IPX203 in Canada and Latin America.

Key Points: 
  • MONTREAL, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today that it has entered into an exclusive license agreement with Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) ("Amneal"), granting Knight the exclusive rights to seek regulatory approval and commercialize IPX203 in Canada and Latin America.
  • IPX203 is a novel, oral formulation of carbidopa/levodopa (CD/LD) extended-release capsules designed for the treatment of Parkinson’s disease.
  • “This transaction builds on our strategy of expanding our CNS portfolio,” said Samira Sakhia, President and CEO of Knight.
  • “We see IPX203 as a critical innovation that can meaningfully advance the standard of care for Parkinson’s patients.”

Knight Therapeutics Announces Product Launch for IMVEXXY® in Canada

Retrieved on: 
Thursday, January 4, 2024

MONTREAL, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today the launch of IMVEXXY® in Canada.

Key Points: 
  • MONTREAL, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today the launch of IMVEXXY® in Canada.
  • “We are very excited about the launch of IMVEXXY®, a new treatment option for postmenopausal women in Canada.
  • Knight and TherapeuticsMD signed a license agreement in July 2018 pursuant to which TherapeuticsMD granted Knight the exclusive Canadian commercialization rights to IMVEXXY® (estradiol vaginal inserts).
  • Under the terms of the license agreement related to IMVEXXY® in Canada, Knight will pay TherapeuticsMD sales milestone fees and royalties based upon certain aggregate annual sales of IMVEXXY® in Canada.

Knight Therapeutics Enters into Exclusive License Agreement with Supernus Pharmaceuticals for Qelbree® (viloxazine) in Canada

Retrieved on: 
Tuesday, December 19, 2023

Qelbree® is an extended-release formulation of viloxazine, a multimodal serotonergic and norepinephrine modulating agent (SNMA), a nonstimulant medication for the treatment of Attention-Deficit Hyperactivity Disorder (ADHD).

Key Points: 
  • Qelbree® is an extended-release formulation of viloxazine, a multimodal serotonergic and norepinephrine modulating agent (SNMA), a nonstimulant medication for the treatment of Attention-Deficit Hyperactivity Disorder (ADHD).
  • Financial terms of the agreement were not disclosed.
  • A third phase 4 clinical trial9 is studying the impact of Qelbree® on co-morbid mood symptoms prevalent in patients with ADHD.
  • "Supernus is proud to support other regions and patients in need of innovative solutions to overcome the challenges of treating a complex disease such as ADHD."

Knight Therapeutics Reports Third Quarter 2023 Results

Retrieved on: 
Thursday, November 9, 2023

Gross margin: For the quarter ended September 30, 2023, gross margin, as a percentage of revenues, was 49% compared to 42% in Q3-22.

Key Points: 
  • Gross margin: For the quarter ended September 30, 2023, gross margin, as a percentage of revenues, was 49% compared to 42% in Q3-22.
  • Selling and marketing (“S&M”): For the quarter ended September 30, 2023, S&M expenses were $11,924, a decrease of $1,532 or 11%, compared to the same period in prior year.
  • General and administrative (“G&A”): For the quarter ended September 30, 2023, G&A expenses were $11,080, an increase of $664 or 6%, compared to the same period in prior year.
  • For the quarter ended September 30, 2023, interest income was $3,055, an increase of $593 or 24%, compared to the same period in prior year.

Notice of Knight Therapeutics' Third Quarter 2023 Results Conference Call

Retrieved on: 
Thursday, November 2, 2023

MONTREAL, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its third quarter 2023 financial results on Thursday, November 9, 2023 prior to market opening.

Key Points: 
  • MONTREAL, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its third quarter 2023 financial results on Thursday, November 9, 2023 prior to market opening.
  • Following the release, Knight will hold a conference call and audio webcast.
  • Knight cordially invites all interested parties to participate in this call.

Knight Therapeutics Announces CMED Price Approval of Minjuvi® (tafasitamab) in Brazil

Retrieved on: 
Monday, October 16, 2023

As a result, Knight expects to launch Minjuvi® in Brazil in the second quarter of 2024.

Key Points: 
  • As a result, Knight expects to launch Minjuvi® in Brazil in the second quarter of 2024.
  • “We’re excited to continue to advance the approval of Minjuvi® in Brazil, a new treatment option for a current unmet need.
  • We look forward to launching Minjuvi® in Brazil and obtaining approval in other key markets in Latin America,” said Samira Sakhia, Knight Therapeutics President and CEO.
  • “Knight’s team is working diligently with physicians, key institutions and payors to ensure patients have access to Minjuvi®,” said Cristiane Coelho, Knight Therapeutics Brazil General Manager.